Polpharma is the largest Polish manufacturer of APIs, i.e. active substances for the manufacture of finished drug forms. Thanks to competitive manufacturing costs, excellent product quality and environment-friendly processes, they are in the position of being a world leader in the manufacture of hydrobisphosphonates (substances used for the treatment of osteoporosis).

Polypharma’s broad and varied portfolio and years of experience allow them to offer modern products and solutions to pharmaceutical companies worldwide. The total capacity of their reactors for substance synthesis is 350,000 litres. Their manufacturing facilities are subject to rigorous inspections by the US Food and Drug Administration (FDA). All FDA inspections (in 2004, 2009, 2012 and 2015) conducted so far have resulted in no objections being raised.